Dashenlin Pharm Grp Co Ltd (603233) — Capital Reinvestment Ratio
Dashenlin Pharm Grp Co Ltd (603233) has a Capital Reinvestment Ratio of 0.20x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥818.72 Million) in capital expenditures (CN¥161.42 Million). See 603233 net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Dashenlin Pharm Grp Co Ltd Capital Reinvestment Ratio (2012–2025)
This chart tracks Dashenlin Pharm Grp Co Ltd's Capital Reinvestment Ratio across 14 annual periods. Check 603233 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Dashenlin Pharm Grp Co Ltd (2012–2025)
Year-by-year Capital Reinvestment Ratio for Dashenlin Pharm Grp Co Ltd from 2012 to 2025. For live market cap and broader valuation context, see 603233 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | CN¥5.35 Billion | CN¥484.84 Million | ▼ -80.9% |
| 2024 | 0.48x | CN¥3.11 Billion | CN¥1.48 Billion | ▼ -16.1% |
| 2023 | 0.57x | CN¥3.17 Billion | CN¥1.80 Billion | ▲ +105.5% |
| 2022 | 0.28x | CN¥3.76 Billion | CN¥1.03 Billion | ▼ -66.9% |
| 2021 | 0.83x | CN¥1.55 Billion | CN¥1.29 Billion | ▲ +105.4% |
| 2020 | 0.41x | CN¥1.95 Billion | CN¥792.32 Million | ▲ +38.1% |
| 2019 | 0.29x | CN¥1.71 Billion | CN¥501.41 Million | ▼ -53.7% |
| 2018 | 0.63x | CN¥873.64 Million | CN¥554.39 Million | ▼ -39.2% |
| 2017 | 1.04x | CN¥640.39 Million | CN¥668.53 Million | ▲ +68.3% |
| 2016 | 0.62x | CN¥495.60 Million | CN¥307.35 Million | ▲ +17.3% |
| 2015 | 0.53x | CN¥468.59 Million | CN¥247.84 Million | ▼ -9.4% |
| 2014 | 0.58x | CN¥448.58 Million | CN¥261.82 Million | ▼ -53.8% |
| 2013 | 1.26x | CN¥288.22 Million | CN¥363.99 Million | ▲ +510.4% |
| 2012 | 0.21x | CN¥289.31 Million | CN¥59.85 Million | — |